Uremia cardiomyopathy, the most important direct cause of death in end stage kidney disease patients, is one of the important cardiovascular complications of chronic kidney disease. Uremia cardiomyopathy is characterized by left ventricular hypertrophy, fibrosis, systolic and/or diastolic dysfunction. The pathogenesis of uremia cardiomyopathy is complex and has not been fully elucidated. This article reviews the recent advances in the pathogenesis of uremia cardiomyopathy from the perspectives of non-traditional cardiovascular risk factors. In addition, we introduce our latest results, and provide a new possible entry point for the research of pathogenesis of uremia cardiomyopathy.